![Emma Vidal: A new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy](https://oncodaily.com/pub/uploads/2024/01/GEIwA90XAAA6Euz-e1706127406859.jpeg)
Photo taken from Rony Dahan/X
Jan 26, 2024, 07:25
Emma Vidal: A new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy
Emma Vidal, Founder of DrawImpacts, shared an X post by Rony Dahan, Principal Investigator at Weizmann Institute of Science, adding:
“We had a blast working with the Rony Dahan and Yuval Shapir Itai to illustrate their latest paper on BiCE (Bispecific DC-T Cell Engager), a new bispecific DC-T cell engager designed to potentiate aPD-1 immunotherapy!
Learn more about their amazing work.”
Quoting Rony Dahan‘s post:
“Together with IdoAmitLab we’re very excited to introduce BiCE (Bispecific DC-T Cell Engager)- a new platform to engineer immune cell communication for cancer immunotherapy. Led by the amazing Yuval Shapir Itai, Oren Barboy, now out in Cell Press Journal.”
Source: Emma Vidal/X and Rony Dahan/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023